Background {#Sec1}
==========

Depression is a common mental disorder primarily characterized by the presence of low spirit, anhedonia, insomnia, loss of appetite, inattention, and even suicide \[[@CR1]\]. In high-income countries, the prevalence depression is approximately 5.1% \[[@CR2]\], and the annual incidence of depression is approximately 3% \[[@CR3]\]. Some studies predict that depression will be the main factor leading to death and disability in high-income countries by the year 2030 \[[@CR4]\]. To date, anti-depressant drugs commonly used in clinics are primarily categorized into two types: a selective serotonin-norepinephrine reuptake inhibitor and a selective 5-hydroxy tryptamine reuptake inhibitor. Although these two types of inhibitors have definite therapeutic efficacies, their long-term usage has severe adverse effects, leading to poor compliance \[[@CR5]\] and subsequent relapse of depression. Therefore, China and other countries are increasing their efforts toidentify traditional Chinese medicines with less adverse effects.

With a deeper understanding of depression in traditional Chinese medicine and in the light of traditional Chinese medicine theories, Chai Hu Shu Gan San is being increasingly used to treat depression. Chai Hu Shu Gan San is described in the Chinese ancient book *Jing Yue Quan Shu • Gu Fang Ba Zhen • San Zhen*, by Jingyue Zhang of the Ming dynasty. The primary constituent of this formula is Chai Hu (*Bupleurum Chinese*). The formula has two other constituents: Xiangfu (*Cyperus rotundus*) and Chuanxiong (*Ligusticum chuanxiong*). In China, a large number of clinical trial studies have indicated that Chai Hu Shu Gan San is widely used for treating all types of depression, however, no publication has been identified to summarize the evidence and evaluate its effect and safety. This study, therefore, aims to systematically review the efficacy and safety of Chai Hu Shu Gan San for the treatment of depression, thereby laying an evidence-based foundation for clinical therapy.

Methods {#Sec2}
=======

Criteria for inclusion and exclusion {#Sec3}
------------------------------------

The criteria for inclusion were as follows: (1) study types: a randomized control trial (RCT)---regardless of blind methods and placebos---that was reported in either Chinese or English; (2) participants: patients with definite diagnosis of depression (Major depressive disorder, MDD), irrespective of the cause or presence of other diseases; (3) interventions: test groups were treated with Chai Hu Shu Gan Yin (San) alone, without restriction of its doses and therapeutic periods, and control groups were treated with placebos, regular Western medicines, or no therapy at all;participants with any concomitant disease in both a test group and a control group were simultaneously subjected to the same treatments, other than the above-mentioned ones, regardless of therapeutic periods, therapeutic methods, and medicine doses; (4) outcome index: the Hamilton Depression Scale (HAMD) scores of the patients, the efficacy rate of the medicines, and theadverseeventsof medicines.

We excluded articles that RCT that did not report outcome indices relevant to this study.

Search strategy {#Sec4}
---------------

Reference searches in PubMed, the Cochrane library, Chongqing VIP database, China National Knowledge Internet (CNKI), and Wanfang database were conducted. The following search terms were included: "Chai Hu Shu Gan", "depression", and "random".The above terms in Chinese were adapted and searched in Chinese databases. The search period was from the time of establishment of each database to January 1, 2017, and the references cited by the retrieved articles were tracked.

Reference screening {#Sec5}
-------------------

For all of the retrieved references, two independent researchers (Yan Sun and Xia Xu) read the titles and abstracts and excluded any studies in which the RCT failed to fulfill the criteria for inclusion. The researchers further read the full text of the remaining articles to determine whether they fulfilled the criteria for inclusion. They then cross-verified their conclusions. If it was difficult for the two researchers to reach a consensus on whether a study should be included, the disagreement was resolved after discussion with a third party.

Methodological quality assessment for the included studies {#Sec6}
----------------------------------------------------------

The methodological quality of the RCTs wasassessed using methods recommended by the Cochrane Collaboration. This approachprimarily involves a risk/bias assessment based onsix items \[[@CR6]\]:the generation of random sequences, concealment of random allocation, blinding method, data completeness, selective reporting of outcomes, and estimation of sample size. If a study fulfilled each aforementioned item, it had a low risk of bias; otherwise, it had a high risk of bias. When it was impossible to assess whether an article fulfilled the aforementioned criteria, because of insufficient information in the article, the study was considered "unclear". The methodological quality assessment of clinical trials was conducted by the two independent researchers (Jinping Zhang and Yuanyuan Chen), and any disagreements were resolved after a discussion with a third party.

Information extraction and analysis {#Sec7}
-----------------------------------

The two researchers used the same information-extraction table to independently extract the information, which primarily included titles, general characteristics of the patients, concomitant diseases, intervention and control measures, follow-up, and indices for the assessment of therapeutic efficacy.

A meta-analysis was conducted with RevMan 5.2.0 software, which was provided by the Cochrane Collaboration. The count data was expressed in terms of odd ratio (OR), and the measurement data was expressed in terms of mean difference (MD) with a 95% confidence interval (CI). The effects were expressed with the random-effects model (REM).

Results {#Sec8}
=======

Procedure for study inclusion {#Sec9}
-----------------------------

In this review, we initially identified 560 relevant studies from 5 databases and 323 duplicate records were removed. The remaining 106 records were screened, in which 38 records were excluded by reading titles and abstracts, 68 records were assessed in full texts, an additional 26 records were excluded for improper participants, irrelevant comparisons, single author, uncertain diagnosis, poor data authenticity, redundant publications, no RCTs or missing data unavailable from contacting the author. 42 trials met the inclusion criteria and were included in the meta-analysis \[[@CR7]--[@CR48]\]. The screening procedure is illustrated in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1PRISMA 2009 Flow Diagram

Description of studies {#Sec10}
----------------------

The 42 studies included in this review were all conducted and published in Chinese from 2006 to 2016. Together, these studies included 3234 patients with depression (consisting of 1784 patients in test groups and 1450 patients in control groups). Among the included investigations, two reported using three groups \[[@CR16], [@CR21]\], while the others reported using two-group parallel control methods. Thirteen studies investigated patients with pure depression \[[@CR9], [@CR18], [@CR19], [@CR23], [@CR32], [@CR34], [@CR35], [@CR37], [@CR40], [@CR43], [@CR44], [@CR46], [@CR47]\], two studies investigated patients with post-partum depression (PD) \[[@CR27], [@CR28]\], while 27 studies investigated patients with other diseases concomitant with depression (consisting of eleven studies about post-stroke depression (PSD) \[[@CR7], [@CR8], [@CR10], [@CR12], [@CR13], [@CR15], [@CR17], [@CR22], [@CR39], [@CR42], [@CR48]\], three about Parkinson's disease concomitant with depression \[[@CR20], [@CR30], [@CR41]\], one each about cancer concomitant with depression \[[@CR11]\], seizures concomitant with depression \[[@CR14]\], chronic pelvic inflammation concomitant with depression \[[@CR16]\], post-percutaneous coronary intervention depression \[[@CR24]\], two studies on digestive diseases concomitant with depression \[[@CR21], [@CR29]\], and two study on cerebral vascular disease concomitant with depression \[[@CR26], [@CR33]\], one study each about chronic obstructive pulmonary disease concomitant with depression \[[@CR25]\], diabetes concomitant with depression \[[@CR38]\], coronary heart disease concomitant with depression \[[@CR31]\], rheumatoid arthritis concomitant with depression \[[@CR36]\] and Cardiac neurosis concomitant with depression \[[@CR45]\]).

Among the included studies in this review, 26 reported therapy for depression with Chai Hu Shu Gan San based on the traditional Chinese medicine hypothesis about syndrome differentiation and treatment, and others reported personalized therapies for depression without using this hypothesis. In 21 studies, treatment of depression was conducted with Chai Hu Shu Gan San alone. In the other studies, treatments involving a combination of Chai Hu Shu Gan San and Western medicines (fluoxetine in seven studies \[[@CR7], [@CR9], [@CR12], [@CR15], [@CR17], [@CR27], [@CR28], [@CR47]\], escitalopram oxalate in one study \[[@CR10], [@CR40]\], venlafaxine hydrochloride in one study \[[@CR19]\], paroxetine hydrochloride in two study \[[@CR22], [@CR41]\], mirtazapine in two study \[[@CR26], [@CR34]\], duloxetine in one study \[[@CR30]\], deanxit in three study \[[@CR13], [@CR42], [@CR45]\], and sertraline hydrochloride in one study \[[@CR20]\]) were investigated. None of the included studies used placebo controls. The therapeutic efficacy in a test group treated with Chai Hu Shu Gan San was compared with that of a control group (no treatment with any therapy in four studies \[[@CR16], [@CR21], [@CR25], [@CR29], [@CR31]\], treated with fluoxetine in 16 studies \[[@CR7]--[@CR9], [@CR11], [@CR12], [@CR15], [@CR17], [@CR18], [@CR27], [@CR28], [@CR32], [@CR33], [@CR39], [@CR43], [@CR47], [@CR48]\], paroxetine in ten studies \[[@CR14], [@CR16], [@CR22], [@CR23], [@CR35], [@CR36], [@CR38], [@CR41], [@CR44], [@CR46]\], deanxit therapy in five studies \[[@CR13], [@CR21], [@CR24], [@CR42], [@CR45]\], and escitalopram oxalate in two studies \[[@CR10], [@CR40]\], mirtazapine in two studies \[[@CR26], [@CR34]\], sertraline hydrochloride \[[@CR20]\], duloxetine \[[@CR30]\], amitriptyline \[[@CR37]\] and venlafaxine therapy \[[@CR19]\] in one study each). Thirty-eight of the included studies employed the HAMD scale, with 33 reporting therapeutic efficacy for depression and 22 reporting the safety of the medications. No study reported the long-term effects by conducting follow-up surveys with subjects.

The characteristics of the included articles are shown in Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of the enrolled randomized controlled trialsStudy IDSample size (I/C)Gender (M/F)AgeIntervention GroupControlled GroupSyndrome DifferentiationCourse of TreatmentFollowing-upOutcomesHAMD Mean score (SD)Effective Rate\
(events/total)Adverse EffectDepression Cheng XY 2007 \[[@CR7]\]33/30I:18/15;\
C:16/14I:37.1 ± 7.6;\
C:36.7 ± 8.7Chai Hu Shu Gan San + FluoxetineFluoxetineY6 weeksN6.32(2.33) vs 7.01(3.45)NRI: somnolence, dry mouth and sleepy;\
C: insomnia, blurred vision, nausea, headache.\
(Case unknown) Lin B 2011 \[[@CR8]\]30/30I:13/17;\
C:15/15I:52.13 ± 4.31;\
C:50.43 ± 4.80Chai Hu Shu Gan SanFluoxetineY20 daysN11.53(7.41) vs 13.23(6.99)26/30 vs 5/30NR Liu YY 2012 \[[@CR9]\]31/32I:11/19;\
C:12/20I:40.5 ± 9.9;\
C:36.6 ± 15.0Chai Hu Shu Gan San + VenlafaxineVenlafaxineY4 weeksN5.9(4.6) vs 8(5.6)NRNR Wang RC 2013 \[[@CR10]\]40/40I:18/22;\
C:21/19I:33.6 ± 10.75;\
C:34.70 ± 11.23Chai Hu Shu Gan SanParoxetineY6 weeksN7.21(4.23) vs 7.52(3.79)33/40 vs 34/40I: slight headache, tiredness,constipation, sweat, bitter taste;\
C: dry mouth, constipation, excitement and agitation, insomnia, dizziness, headache, palpitation, quiver, nausea, vomit, sexuality descent, ejaculation inhibition, female sexual lack. (Case unknown) Shao XQ 2016 \[[@CR11]\]15/13I:8/7;\
C:7/6I:37.4 ± 7.53;\
C:36.7 ± 7.61Chai Hu Shu Gan SanFluoxetineY6 weeks6 months9.51(4.84) vs 10.24(4.01)14/15 vs 12/13No adverse effect reported in intervention group;Nausea, anorexia, headache, sexual dysfunction reported in control group (Case unknown) Gu XX 2016 \[[@CR12]\]30/30I:18/12\
C:16/14I:33.1 ± 14.4\
C:32.8 ± 17.1Chai Hu Shu Gan San + MirtazapineMirtazapineN8 weeksN7.82(1.56) vs 15.88 (1.42)27/30 vs 24/30Appetite increased, weight gain, edema, nausea, dry mouth, sleep disorders (Case unknown) Hu J 2015 \[[@CR13]\]48/48I:20/28\
C:22/26I:38.56 ± 12.23\
C:39.89 ± 11.83Chai Hu Shu Gan SanParoxetineN6 weeksN9.65(3.44) vs C:8.98(4.32)43/48 vs 42/48NR Liu CY 2015 \[[@CR14]\]35/34I:21/14C:19/15I:49.12 ± 7.64\
C:48.46 ± 7.25Chai Hu Shu Gan San + AmitriptylineAmitriptylineY3 monthsN4.83(1.37) vs 4.79(1.02)33/35 vs 28/34constipation (I = 1 vs C = 7/34); dry mouth (I = 0 vs C = 4); dizzy(I = 1 vs C = 5);electrocardiographic abnormality (I = 1 vs C = 6) Deng SZ 2012 \[[@CR15]\]53/48I:28/25;\
C:23/25NAChai Hu Shu Gan San + CitalopramCitalopramY8 weeksN6.07(1.86) vs 9.38(2.27)49/53 vs 37/48NR Song YM 2011 \[[@CR16]\]30/30I:11/19;\
C:12/18I:46.5 ± 6.3;\
C:45.3 ± 7.2Chai Hu Shu Gan SanFluoxetineY4 weeksN14.8(3.3) vs 17.6(2.8)28/30 vs 24/30NR Fan QL 2008 \[[@CR17]\]70/35I:28/42;\
C:13/22I:67.5;\
C:67.5Chai Hu Shu Gan SanParoxetineY3 monthsNNR69/70 vs 29/35NR Deng GQ 2013 \[[@CR18]\]30/30I:13/17;\
C:12/18I:38.5 ± 10.4;\
C:40.2 ± 12.1Chai Hu Shu Gan SanParoxetineY6 weeksN8.9(3.5) vs 9.7(2.8)24/30 vs 22/30NR Wang L 2012 \[[@CR19]\]30/30I:12/18;\
C:14/16NAChai Hu Shu Gan San + FluoxetineFluoxetineY4 weeksNNR28/30 vs 25/30Insomnia, mental tension, nausea, headache (C = 9 vs I = 3)Post-stroke Depression Chang XH 2010 \[[@CR20]\]50/50I:31/19;\
C:28/22I:42--74;\
C:45--75Chai Hu Shu Gan San + FluoxetineFluoxetineY28 daysN10.24(3.4) vs 14.2(2.7)48/50 vs 41/50NR Chen HH 2013 \[[@CR21]\]47/47I:30/17;\
C:29/18I:67 ± 4;\
C:66 ± 5Chai Hu Shu Gan SanFluoxetineN4 weeksN5.82(1.56) vs 6.21(1.38)43/47 vs 42/47Nausea (I = 1 vs C = 14), nodal tachycardia (I = 0 vs C = 5), stomach discomfort (I = 2 vs C = 15), dry mouth (I = 2 vs C = 18), somnolence (I = 1 vs C = 15); Cui Y 2016 \[[@CR22]\]30/30I:18/12;\
C:16/14I:52.23 ± 9.90;\
C:50.73 ± 10.52Chai Hu Shu Gan San + Escitalopram Oxalate TabletsEscitalopram Oxalate TabletsY6 weeksN8.67(4.97) vs 12.4(6.97)NRno apparent adverse effect in both group. He XM 2007 \[[@CR23]\]36/18I:21/15;\
C:11/7I:53.24 ± 6.31;\
C:54.36 ± 4.42Chai Hu Shu Gan San + FluoxetineFluoxetineN60 daysN16.41(2.56) vs 22.06(3.35)32/36 vs 11/18digestive discomfort (I = 8 vs C = 10), vegetative nerve functional disturbance (I = 10 vs C = 9); Huang WX 2010 \[[@CR24]\]32/31I:17/15;\
C:16/15I:65 ± 4.6;\
C:61 ± 5.3Chai Hu Shu Gan San + DeanxitDeanxitY8 weeksN15.6(4.4) vs 16.2(4.9)NRI; dizziness (2 cases), constipation (1 cases);\
C: No adverse effect Huang YS 2012 \[[@CR25]\]39/39I:22/17;\
C:20/19I:62.51 ± 7.47;C:61.93 ± 7.82Chai Hu Shu Gan San + FluoxetineFluoxetineY3 monthsN9.57(2.11) vs 13.08(2.58)35/39 vs 32/39I: No adverse effect;\
C: 6 cases with dry mouth, nausea, vomit, appetite reduced, insomnia, headache, tiredness. Lian Z 2009 \[[@CR26]\]30/30I:17/13;\
C:16/14I:56.20 ± 18.6;\
C:54.6 ± 17.5Chai Hu Shu Gan San + FluoxetineFluoxetineN60 daysN6.21(2.53) vs 12.1(1.25)26/30 vs 24/30gastrointestinal discomfort (I = 6 vs C = 14), Autonomic nerve dysfunction (I = 7 vs C = 16) Wang GL 2009 \[[@CR27]\]66/66I:24/40;\
C:28/38I:63.5 ± 2.3;\
C:64.5 ± 3.4Chai Hu Shu Gan San + ParoxetineParoxetineY6 weeksN7.2(2.1) vs 10.1(1.7)62/66 vs 52/66NR Ji XL 2013 \[[@CR28]\]30/30I:18/12\
C:17/13NAChai Hu Shu Gan SanFluoxetineY30 daysN9.1(3.2) vs 13.3(3.5)25/30 vs 19/30NR Zhang FH 2013 \[[@CR29]\]40/40I:18/22\
C:16/24I:66.3;\
C:65.8Chai Hu Shu Gan San + DeanxitDeanxitY6 weeksN14.2(2.1) vs 17.3(2.6)36/40 vs 31/40NR Ren MJ 2015 \[[@CR30]\]36/3641/3158.6 ± 2.1Chai Hu Shu Gan SanFluoxetineY30 daysN8.2(2.6) vs 14.1(2.8)35/36 vs 30/36Dry mouth, nausea, anorexia, fatigue (I = 0 vs C = 4)Postnatal Depression Zhao XP 2006 \[[@CR31]\]45/42I:0/45;\
C:0/42I:29.04 ± 3.99;\
C:29.12 ± 4.26Chai Hu Shu Gan San + FluoxetineFluoxetineY4 weeksN9.18(5.72) vs 11.36(5.73)43/45 vs 39/42Nausea, appetite descent, anxiety, somnipathy, quiver (Case unknown). Zhao Y 2016 \[[@CR32]\]41/42I:0/41;\
C:0/42I:28.94 ± 5.03;\
C:30.12 ± 4.3Chai Hu Shu Gan San + FluoxetineFluoxetineN8 weeksN8.31(2.05) vs 13.96(2.16)NRDry mouth, dizziness, nausea, tiredness, somnolence, quiver (I = 3 vs C = 10)Cancer and Depression Fang XH 2013 \[[@CR33]\]45/45I:17/28;\
C:24/21I:42.3 ± 18.1;\
C:47.6 ± 16.9Chai Hu Shu Gan SanFluoxetineN6 weeksN11.78(3.21) vs 13.98(2.12)38/45 vs 34/45Dry mouth (I = 2 vs C = 3), constipation (I = 2 vs C = 0), dizziness and headache (I = 3 vs C = 2),insomnia (I = 4 vs C = 1), gastrointestinal dysfunction (I = 7 vs C = 2), blurred vision (I = 2 vs C = 0)Epilepsy and Depression Huang XB 2015 \[[@CR34]\]62/6064/5837.28 ± 7.29Chai Hu Shu Gan SanParoxetineN12 weeksN17.68(1.95) vs 22.12(1.9)41/57 vs 25/54NRChronic Pelvic Inflammation and Depression Li L 2006 \[[@CR35]\]38/36/38I:0/38;\
C1:0/36;\
C2:0/38N/AChai Hu Shu Gan SanC1: Paroxetine; C2: No InterventionN6 weeksN17.71(3.91) vs C1:18.55(4.51); C2: 22.00(3.91)34/38 vs C1:28/36; C2:18/38NRPost-PCI and Depression Wang YT 2016 \[[@CR36]\]30/30NANAChai Hu Shu Gan SanDeanxitN4 weeksN15.73(6.05) vs 14.77(6.84)25/30 vs 23/30NRCOPD and Depression Yang G 2011 \[[@CR37]\]40/40I:24/16;\
C:22/18I:62.37 ± 6.78;\
C:63.6 ± 7.25Chai Hu Shu Gan SanNo InterventionN4 weeksN14.59(1.12) vs 20.15(1.08)34/40 vs 20/40NRParkinson and Depression Ma YZ 2011 \[[@CR38]\]36/32NANAChai Hu Shu Gan San + Sertraline HydrochlorideSertraline HydrochlorideY4 weeksN9.2(3.6) vs 12.3(5.4)NRNR Zhou R 2016 \[[@CR39]\]36/36I:18/18;\
C:16/20NAChai Hu Shu Gan San + DuloxetineDuloxetineY4 weeksN15.96(3.96) vs 20.28(3.56)NRNausea (I = 2 vs C = 2), headache (I = 0 vs C = 1) Yang MJ 2010 \[[@CR40]\]30/30I:18/12; C:17/13I:62 ± 6.53;\
C:62.13 ± 5.92Chai Hu Shu Gan San + ParoxetineParoxetineY8 weeksN9.02(1.24) vs 13.12(2.72)27/30 vs 21/30Dry mouth (I = 2 vs C = 5); fatigue (I = 1 vs C = 3); Nausea (I = 2 vs C = 3); poor appetite (I = 4 vs C = 5); insomnia (I = 2 vs C = 5); constipation (I = 2 vs C = 5)Piman syndrome and Depression Qiu ZJ 2012 \[[@CR41]\]36/36/36I:17/19;\
C1:16/20;\
C2:17/19I:36.17 ± 13.29;\
C1:36.17 ± 11.29;\
C2:38.83 ± 11.94Chai Hu Shu Gan SanC1:Deanxit;\
C2: No InterventionN6 weeksN6.42(3.68) vs C1:5.42(4.14); C2:16.03(4.34)NRMouth odor, nausea, vomit, inappetence, gastrointestinal dysfunction, diarrhea, constipation in three groups, (Case unknown)Cerebrovascular disease and Depression Yao K 2013 \[[@CR42]\]38/38I:20/18;\
C:19/19I:65.27 ± 8.35;\
C:66.31 ± 7.94Chai Hu Shu Gan San + MirtazapineMirtazapineY4 weeksN12.53(3.17) vs 15.87(3.62)34/38 vs 30/38Dry mouth, nausea, constipation (Case unknow) Shang GM 2014 \[[@CR43]\]29/29I:17/12;\
C:16/13I:63.38 ± 10.21; C:62.91 ± 9.83Chai Hu Shu Gan SanFluoxetineN4 weeksNNR27/29 vs 23/29NRGastroesophageal Reflux Disease and Depression Zheng YJ 2016 \[[@CR44]\]43/42I:18/25;\
C:17/25I:32.3 ± 12.6;\
C:44.2 ± 7.4Chai Hu Shu Gan SanNo InterventionN8 weeksN9.2(1.3) vs 14.3(1.8)40/43 vs 32/42Nausea (I = 1 vs C = 5), dry mouth (I = 0 vs C = 2), dizziness (I = 0 vs C = 4)Coronary heart disease and Depression Liu YH 2014 \[[@CR45]\]25/24I:14/11;\
C:13/11I:60.7 ± 13.6;\
C:56.8 ± 10.2Chai Hu Shu Gan SanNo InterventionN4 weeksNNR19/25 vs 9/24No adverse effect reported in both groupsRheumatoid arthritis and Depression Chen PY 2015 \[[@CR46]\]34/34NANAChai Hu Shu Gan SanParoxetineN6 weeksN10.68(6.83) vs 19.31(7.69)NRNRDiabetes and Depression Yang YL 2013 \[[@CR47]\]40/38I:18/22; C:15/23I:38.70 ± 11.10; C:37.5 ± 11.2Chai Hu Shu Gan SanParoxetineY3 monthsN14.12(7.84) vs 22.69(11.66)38/40 vs 28/38NRCardiac neurosis and Depression Pei GX 2013 \[[@CR48]\]60/60I:18/42; C:24/36I:42.58 ± 6.12; C:44.32 ± 4.58Chai Hu Shu Gan San + DeanxitDeanxitY8 weeksN11.42(3.45) vs 13.68(2.74)57/60 vs 53/60NR**Note:**Y\-\--Yes; N\-\--No; I\-\--Interventional Group; C\-\--Controlled Group; F\-\--Female; M\-\--Male; HAMD\-\--Hamilton Depression Scale; SD\-\--standard deviation; NR\-\-- not reported

Methodological quality {#Sec11}
----------------------

In thisreview, we employed a quality standard of RCT evidence recommended by the Cochrane Collaboration to assess the risk of bias in the included studies. The studies included in this review were all assessed, and determined to contain high risks of bias, and were subsequently considered to be of low quality. None of the included articles contained details regarding placebos, blinding methods, or concealment of random sequences. Nine studies used a random number table for random allocation \[[@CR7], [@CR8], [@CR11]--[@CR14], [@CR16], [@CR28], [@CR38]\]. And one article used random allocation based on whether the patient's bed number was odd or even was considered to have a high risk of bias \[[@CR15]\]. The other studies only mentioned "random allocation", and their risks of bias were considered to be "unclear". Only two study reported a withdrawal from the trial \[[@CR19], [@CR31]\], and the bias of incomplete outcome reporting in the article was considered to have a "low risk", while the other studies did not provide clear information, and their biases of "incomplete outcome" reporting were considered to be "unclear". None of the included studies registered their protocols. By comparing the predicted outcome indices in the studies---estimated based on the methodology section in the articles---with the real reported outcome indices in the same studies, this review assessed whether there existed any risk of selective outcome reporting. It was found that five studies showed inconsistencies between the predicted outcomes and the reported outcomes, and therefore, were considered to have a "high risk" of bias, while the other studies were considered to have a "low risk" of bias. The methodological qualities of the included studies are shown in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Risk of bias summary

Efficacy of Chai Hu Shu Gan San {#Sec12}
-------------------------------

### HAMD evaluation {#Sec13}

Thirty-eight of the reviewed studies reported HAMD data. Total meta analyses showed better effect of Chai Hu Shu Gan San than controls (MD = − 3.29, from − 4.09 to − 2.50, I^2^ = 95%), and subgroup meta analyses also showed it favorites compared to fluoxetine for pure depression (MD = − 1.59, from − 2.82 to − 0.37, 4 trials, I^2^ = 26%), and better than fluoxetine for post-stroke depression (MD = − 4.20, from − 6.20 to − 2.19, 7 trials, I^2^ = 96%), and better than fluoxetine for postpartum depression (MD = − 4.10, from − 7.48 to − 0.72 7 trials, I^2^ = 86%). More details regarding the HAMD score improvement in depression treatment with Chai Hu Shu Gan San are given in Fig. [3](#Fig3){ref-type="fig"}.Fig. 3Forest plot for HAMD improvement after treatment of depression with Chai Hu Shu Gan San

### Efficacy rate {#Sec14}

There were 33 studies reporting the efficacy rate of Chai Hu Shu Gan San for treating depression. Total meta-analysis showed that the Chai Hu Shu Gan San had a significantly higher efficacy rate than controls (OR = 2.94, from 2.29 to 3.77, I^2^ = 9%), and subgroup meta analyses showed it better effect than fluoxetine alone for treating pure depression (OR = 6.51, from 0.93 to 45.33, 3 trials, I^2^ = 68%), and also for treating post stroke depression (OR = 2.62, from 1.52 to 4.52, 7 trials, I^2^ = 0%,). Figure [4](#Fig4){ref-type="fig"} shows the efficacy rate of Chai Hu Shu Gan San for treating depression.Fig. 4Forest plot for efficacy rate of Chai Hu Shu Gan San in treating depression

### Adverse events {#Sec15}

None of the included studies reported severe adverse events of Chai Hu Shu Gan San. Among the 21 studies that compared the therapeutic effects between Chai Hu Shu Gan San alone and regular Western medicines for treating depression, thirteen of them did not report the safety indices. The other studies reported drug-induced symptoms such as nausea, dry mouth, and dizziness, and the symptoms in the test group treated with Chai Hu Shu Gan San were fewer than those in the control group (dry mouth: OR = 0.17, from 0.05 to 0.53, 4 trials, I^2^ = 13%; nausea: RR = 0.04, from 0.02 to 0.37, two trials, I^2^ = 0%, FEM). Among the 21 studies that compared the therapeutic efficacy of a combination of Chai Hu Shu Gan San and a Western medicine with that of the Western medicine alone for treating depression, seven did not report safety indices, reported that "there was no adverse effect in the two groups", and the others reported many adverse effects, however, with inconsistencies in the assessment methods. Therefore, it was impossible for us to conduct a further quantitative analysis of their data. However, all of the aforementioned studies that reported adverse effects noted that the side effects in a Chinese-Western medicine combination group were fewer than those in a Western medicine group, and the side effects in both groups were likely to be induced by the same Western medicine used in each group.

Discussion {#Sec16}
==========

Depression is not a simple disease. It is a neural disorder involving many pathological factors and pathophysiological symptoms. Patients with depression included in this review suffered from12different types of diseases. The meta-analysis indicated that a combination of Chai Hu Shu Gan San and fluoxetine was better than fluoxetine alone for treating PSD and PD. Meanwhile, no exact data indicated Chai Hu Shu Gan San has fewer adverse effects than regular Western medicines, so the safety of Chan Hu Shu Gan San in treating depression is worthy to be further investigated.

Chai Hu Shu Gan San is composed of 3 key herbs: Chai Hu (*Bupleurum Chinese*), Xiangfu (*Cyperus rotundus*),and Chuanxiong (*Ligusticum chuanxiong*). *Bupleurum Chinese*iswell known for its anti-inflammatory actions \[[@CR49]\] and neuroprotective effects \[[@CR50]\]. It has also been explored extensively for antioxidant, anticancer, and apoptotic properties in treating other diseases \[[@CR51], [@CR52]\]. Recently, *Cyperus rotundus*has been found to have anti-inflammatory activity in both the peripheral and central nervous system \[[@CR53]--[@CR55]\]. Moreover, *Ligusticum chuanxiong* is a classic herb with anti-inflammatory effects in treatingcardiovascular and cerebrovascular diseases \[[@CR56], [@CR57]\], and its conventional activity tends to be neuroprotectivein a translational medicine perspective \[[@CR58], [@CR59]\]. Depression has serious neurological symptoms, and theoretically, Chai Hu Shu Gan San, because of the above 3 key herbs, is a better choice for the treatment of the disease.

There are some limitations. First, the methodological qualityof the included studies was not high. Therefore, the studies were likely to have certain degrees of subjective bias. Second, the included studies in this review did not have long-term follow-up data. Therefore, we were unable to assess the relapse rate and long-term quality of life of the patient. Third, patients with depression in the included studies had many different kinds of diseases, involving many diseases and conditions associated with depression, and they were subjected to different interventions and control measures. Therefore, many types of meta-analyses would be subjected to a large degree of limitations. For these reasons, our review could not pool all the data together to conduct meta-analyses. Fourth, there existed high heterogeneity in the conducted meta-analyses, likely due to differences in the approaches that were employed by the different studies for the assessment of depression degree, primary diseases, and HAMD scores. Fifth, all of the included studies employed different assessment standards for assessing efficacy rates, and the investigations that took into consideration the improvement in primary diseases when defining efficacy rates were not included for analysis in this review. Our review only focused on the efficacy rates that were defined primarily based on the improvement in the depression symptoms. Sixth, the reporting of safety indices in the articles was not standard. Because the recruited patients in the different studies had different conditions, and because the patients were treated with different regular Western medicines in addition to Chai Hu Shu Gan San, a variety of adverse effects were observed. Moreover, the adverse effects were presented in different ways. Therefore, it was not possible to provide a quantitative assessment of all safety indices for Chai Hu Shu Gan San. Finally, all the trials were conducted in China mainland and published in Chinese, this may involve publication bias.

Here, we have to discuss the research designs of intervention and comparison. A new intervention is usually pre-estimated effective and safe. However, investigators cannot draw a definite conclusion without a correct comparison design. To avoid measurement bias, Chinese medicine clinical researchers have to focus on research design, especially with respect to intervention and comparison, for further analysis. Most trials included in this review adopted the Chinese medicine or integrative medicine intervention group compared with the western medicine controlled group, which increased the possibility of measurement biases and resultant incorrect conclusions. Hence, in further research, clinical investigators should focus on the intervention and comparison design and try to adopt Chinese placebos in the controlled group. This can reduce the possibility of measurement bias and provide reasonable clinical evidence.

It has been suggested that in the future, a meticulously designed, large-scale, multi-center RCT should be conducted to further verify the therapeutic efficacy of this Chinese medicine before a more reliable conclusion may be finally obtained.

Conclusions {#Sec17}
===========

This study found that Chai Hu Shu Gan San may have some advantages in treating depression, especially PSD and PD. A meticulously designed and conducted RCT is urgently needed to further determine its safetyand efficacy.

CI

:   Confidence interval

CNKI

:   China National Knowledge Internet

COPD

:   Chronic obstructive pulmonary disease

FEM

:   Fixed-effects model

HAMD

:   Hamilton depression scale

MD

:   Mean difference

MDD

:   Major depressive disorder

PCI

:   Post-percutaneous coronary intervention

PD

:   Post-partum depression

PSD

:   Post-stroke depression

RCT

:   Randomized controlled trial

REM

:   Random-effects model

RR

:   Relative risk
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